Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma

Reviews on Recent Clinical Trials

Volumn 3, Issue 1, 2008, Pages 2-9

  Rainov, Nikolai G ^a,b   Gorbatyuk, K ^c   Heidecke, V ^a,b  

^a KLINIKUM AUGSBURG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c Department of Neurosurgery   (Ukraine)

Author keywords

Convection enhanced delivery; Glioblastoma; Glioma; Targeted toxin

Indexed keywords

ANTICONVULSIVE AGENT; CINTREDEKIN BESUDOTOX; IMMUNOTOXIN; INTERLEUKIN 4 PSEUDOMONAS AERUGINOSA EXOTOXIN FUSION PROTEIN; LOMUSTINE; NBI 3001; NITROSOUREA DERIVATIVE; PLATINUM DERIVATIVE; PROCARBAZINE; RECOMBINANT PROTEIN; STEROID; TEMOZOLOMIDE; TP 38; TRANSFERRIN CRM 107; TRANSFORMING GROWTH FACTOR ALPHA PSEUDOMONAS AERUGINOSA EXOTOXIN FUSION PROTEIN; TRANSMID; UNCLASSIFIED DRUG; VINCRISTINE;

APHASIA; ATAXIA; BRAIN EDEMA; BRAIN SURGERY; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTINUOUS INFUSION; CONVECTION ENHANCED DELIVERY SYSTEM; CONVULSION; DIFFUSION TENSOR IMAGING; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FACIAL NERVE PARALYSIS; FATIGUE; GAIT DISORDER; GLIOBLASTOMA; HEMIPARESIS; HUMAN; HYPESTHESIA; INTRACRANIAL PRESSURE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CONVECTION; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTOXINS; INFUSIONS, INTRALESIONAL; TOXINS, BIOLOGICAL;

EID: 39449114014     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488708783330521     Document Type: Review

References (50)

1. Kleihues P, Cavence WK Eds, Pathology and genetics of tumours of the nervous system. Lyon, IARC Press, 2000.
2. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23.
3. Mitchell P, Ellison DW, Mendelow AD. Surgery for malignant gliomas: mechanistic reasoning and slippery statistics. Lancet Neurol 2005; 4: 413-22.
4. Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neurooncology 1999; 1: 205-11.
5. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1: 459-68.
6. Hess CF, Schaaf JC, Kortmann RD, et al. Malignant glioma: patems of failure following individually tailored limited volume irradiation. Radiotber Oncol 1994; 30: 146-9.
7. Schiff D, Shaffrey ME. Role of resection for newly diagnosed malignant gliomas. Expert Rev Anticancer Ther 2003; 3: 621-30.
8. Whittle IR. Surgery for gliomas. Curr Opin Neurol 2002; 5: 663-9.
9. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
10. Janus TJ, Kyritsis AP, Forman AD, et al. Biology and treatment of gliomas. Ann Oncol 1992; 3: 423-33.
11. Saleman M. Malignant glioma management. Neurosurg Clin N Am 1990; 1: 49-63.
12. Schiffer D, Cavalla P, Dutto A, et al. Cell proliferation and invasion in malignant gliomas. Anticancer Res 1997; 17: 61-9.
13. Swanson KR, Alvord EC Jr, Murray JD. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. Br J Cancer 2002; 86: 14-18.
14. Guha A, Mukherjee J. Advances in the biology of astrocytomas. Curr Opin Neurol 2004; 17: 655-62.
15. Pastan I, Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev 1998; 31: 53-88.
16. Hall WA, Fodstad O. Immunotoxins and central nervous system neoplasia. J Neurosurg 1992; 76: 1-12.
17. Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997; 87: 586-94.
18. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-8.
19. Chen MY, Lonser RR, Morrison PF, et al. Variable affecting convection-enbanced delivery to the striatum: a systematic examination of rate of infusion, cannala size, infusate concentration, and tissue-cannula sealing titre. J Neurosurg 1999; 90: 315-20.
20. Puri RK, Leland P, Kreitman RJ, et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994; 58: 574-81.
21. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000; 6: 326-34.
22. Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permitted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996; 56: 5631-7.
23. Puri RK, Siegel JP. Interleukin-4 and cancer therapy. Cancer Invest 1993; 11: 473-86.
24. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncology 2003 64: 125-37.
25. http://clinicaltrials.gov, study identifier NCT00014677
26. Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987; 84: 6899-903.
27. Humphrey PA, Wong AJ, Vogelstein B, et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenographs. Cancer Res 1988; 48: 2231-8.
28. Liberman TA, Nusbaum HF, Razon N, et al. Amplification, enhanced expression, and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985; 313: 144-7.
29. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncology 2003; 65: 27-35.
30. Weber F. Preliminary results of a phase II study of TP-38 immunotoxin delivered via convection-enhanced delivery to patients with recurrent glioblastoma multiforme: report of the TP-38 study group. Annual Meeting of the German Society of Neurosurgery, http://www.egms.de/ en/meetings/dgnc2005/05dgnc0094.htm
31. l Husain SR, Puri RK. Interleuikin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncology 2003; 65: 37-48.
32. Weingart J, Strauss LC, Grossman SA, et al. Phase I/II study: intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma. Neurooncology 2002; 4: 379.
33. Kunwar S: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase I studies. Acta Neurochir Suppl 2003; 88: 105-11.
34. Kunwar S, Prados M, Chang S, et al. Peritumoral convection-enhanced delivery of EL13-PE38QQR in patients with recurrent malignant glioma - phase I interim results. Neurooncology 2003; 5:4.
35. Chang SM. Neuroradiographic changes following convection-enhanced delivery (CED) of the conjugated toxin IL13-PE38QQR following resection of recurrent malignant glioma. Neurooncology 2003; 5:4.
36. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003; 65: 37-48.
37. Prados MD, Lang FF, Stauss LC, et al. Intratumoral and intracerebral microinfusion of IL13-PE38QQR cytotoxin: phase I/II study of pre-and post-resection infusions in recurrent resectable maliganant glioma. Proc Am Soc Clin Oncol 2002; 21: 2087.
38. Ram Z, Barnett G, Vogelbaum M, et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: A phase I(II study. Proc Am Soc Clin Oncol 2003; 22: 403.
39. http://clinicaltrials.gov, study identifier NCT00076986, www.precisetrial.com
40. http://www.allbusiness.com/services/business-services/39804261.htm#
41. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65: 3-13.
42. Recht L, Torres CO, Smith TW, et al. Transferrin recepto in normal and neoplastic brain tissue: implications for brain tumor im-munotherapy. J Neurosurg 1990; 72: 941-5.
43. Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature 1984; 312: 162-3.
44. Johnson VG, Wrobel C, Wilson D, et al. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989; 70: 240-8.
45. http://clinicaltrials.gov, study identifier NCT00083447, see also NCT00088 400 and NCT00087230
46. Chiocca EA, Broaddus WC, Gillies GT, et al. Neurosurgical delivrry of chemotherapeutics, targeted toxins, genetic and viral therapies in neurooncology. Neurooncol 2004; 69: 101-17.
47. Vandergrift WA; Patel SJ. Convection-enhanced delivery: targeted toxin treatment of malignant glioma. Neurosurg focus 2006; 20: E10.
48. Briellmann RS, Pell GS, Wellard RM, et al. MR imaging of epilepsy: state of the art at 1.5 T and potential of 3 T. Epileptic Disord 2003; 5: 3-20.
49. Tummala RP, Chu RM, Liu H, et al. Application of diffusion tensor imaging to magnetic-resonance-guided brain tumor resection. Ped Neurosurg 2003; 39: 39-43.
50. Cruz LC Jr., Sorensen AG. Diffusion tensor magnetic resonance imaging of brain tumors. Neurosurg Clin N Am 2005; 16: 115-34.